Sanofi (SNW) Stock Forecast & Price Target

33 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SNW Analyst Ratings

Moderate Buy

5 Buy

4 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Sanofi

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SNW Stock 12 Month Forecast

Average Price Target

€94.40

▲(23.97% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is €94.40 with a high forecast of €106.21 and a low forecast of €78.00. The average price target represents a 23.97% change from the last price of €76.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"72":"€72","107":"€107","80.75":"€80.8","89.5":"€89.5","98.25":"€98.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":106.21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€106.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.40125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€94.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€78.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[72,80.75,89.5,98.25,107],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.16,76.62538461538462,79.09076923076923,81.55615384615385,84.02153846153846,86.48692307692308,88.95230769230768,91.4176923076923,93.88307692307691,96.34846153846154,98.81384615384614,101.27923076923076,103.74461538461537,{"y":106.21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.16,75.71701923076922,77.27403846153845,78.8310576923077,80.38807692307692,81.94509615384615,83.50211538461538,85.05913461538462,86.61615384615385,88.17317307692308,89.7301923076923,91.28721153846155,92.84423076923078,{"y":94.40125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,74.16,74.45538461538462,74.75076923076922,75.04615384615384,75.34153846153846,75.63692307692307,75.93230769230769,76.22769230769231,76.52307692307693,76.81846153846153,77.11384615384615,77.40923076923077,77.70461538461538,{"y":78,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":75.763,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.233,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.451,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.075,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.844,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.652,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.454,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.117,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.462,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.602,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.18,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.14,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.16,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€106.21

Average Price Target€94.40

Lowest Price Target€78.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Leuchten

Jefferies

€100

Buy

31.32%

Upside

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Qiagen (NYSE: QGEN) and Sanofi (Other OTC: SNYNF)

Justin Smith

Bernstein

€107→€106.21

Buy

39.47%

Upside

Reiterated

08/04/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Luisa Hector

Berenberg Bank

€105

Buy

37.89%

Upside

Reiterated

08/03/26

Analysts Conflicted on These Healthcare Names: Sanofi (Other OTC: SNYNF), Ligand Pharma (NASDAQ: LGND) and Exelixis (NASDAQ: EXEL)

Matthew Weston

UBS

€88→€78

Hold

2.43%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF), Guardant Health (NASDAQ: GH) and Pfizer (NYSE: PFE)

Elmar Kraus

DZ BANK AG

―

Buy

―

Reiterated

07/31/26

Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), Sanofi (SNYNF)

Richard Vosser

J.P. Morgan

€95

Hold

24.75%

Upside

Reiterated

07/31/26

Sanofi (SNYNF) Gets a Hold from J.P. Morgan

Sachin Jain

Bank of America Securities

€92

Hold

20.81%

Upside

Reiterated

07/30/26

Analysts' Top Healthcare Picks: Tilray (TLRY), Humana (HUM)

James Quigley

Goldman Sachs

€89→€84

Hold

10.31%

Upside

Reiterated

07/06/26

Analysts Offer Insights on Healthcare Companies: Celcuity (NASDAQ: CELC), Dogwood Therapeutics (NASDAQ: DWTX) and Sanofi (Other OTC: SNYNF)

Emmanuel Papadakis

Deutsche Bank

€100→€95

Buy

24.75%

Upside

Reiterated

06/15/26

Deutsche Bank Keeps Their Buy Rating on Sanofi (SNYNF)

Nicolas Pauillac

Kepler Capital

€85

Hold

11.62%

Upside

Reiterated

04/23/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF) and Sanofi (Other OTC: SNYNF)

James Gordon CFA

Barclays

€85

Hold

11.62%

Upside

Reiterated

04/23/26

Analysts Conflicted on These Healthcare Names: BridgeBio Oncology Therapeutics (NASDAQ: BBOT), Sanofi (Other OTC: SNYNF) and Molina Healthcare (NYSE: MOH)

Graham Parry

Citi

€85→€80

Hold

5.06%

Upside

Reiterated

02/20/26

Sanofi price target lowered to EUR 80 from EUR 85 at CitiSanofi price target lowered to EUR 80 from EUR 85 at Citi

David Risinger

Leerink Partners

―

Buy

―

Reiterated

12/24/25

Analysts' Top Healthcare Picks: Sanofi (SNYNF), Genmab (GMAB)

Rajesh Kumar

HSBC

€102→€100

Buy

31.32%

Upside

Reiterated

12/10/25

Sanofi price target lowered to EUR 100 from EUR 102 at HSBCSanofi price target lowered to EUR 100 from EUR 102 at HSBC

Seamus Fernandez

Guggenheim

€104→€101

Buy

32.63%

Upside

Reiterated

10/08/25

Sanofi price target lowered to EUR 101 from EUR 104 at GuggenheimSanofi price target lowered to EUR 101 from EUR 104 at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Leuchten

Jefferies

€100

Buy

31.32%

Upside

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Qiagen (NYSE: QGEN) and Sanofi (Other OTC: SNYNF)

Justin Smith

Bernstein

€107→€106.21

Buy

39.47%

Upside

Reiterated

08/04/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Luisa Hector

Berenberg Bank

€105

Buy

37.89%

Upside

Reiterated

08/03/26

Analysts Conflicted on These Healthcare Names: Sanofi (Other OTC: SNYNF), Ligand Pharma (NASDAQ: LGND) and Exelixis (NASDAQ: EXEL)

Matthew Weston

UBS

€88→€78

Hold

2.43%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF), Guardant Health (NASDAQ: GH) and Pfizer (NYSE: PFE)

Elmar Kraus

DZ BANK AG

―

Buy

―

Reiterated

07/31/26

Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), Sanofi (SNYNF)

Richard Vosser

J.P. Morgan

€95

Hold

24.75%

Upside

Reiterated

07/31/26

Sanofi (SNYNF) Gets a Hold from J.P. Morgan

Sachin Jain

Bank of America Securities

€92

Hold

20.81%

Upside

Reiterated

07/30/26

Analysts' Top Healthcare Picks: Tilray (TLRY), Humana (HUM)

James Quigley

Goldman Sachs

€89→€84

Hold

10.31%

Upside

Reiterated

07/06/26

Analysts Offer Insights on Healthcare Companies: Celcuity (NASDAQ: CELC), Dogwood Therapeutics (NASDAQ: DWTX) and Sanofi (Other OTC: SNYNF)

Emmanuel Papadakis

Deutsche Bank

€100→€95

Buy

24.75%

Upside

Reiterated

06/15/26

Deutsche Bank Keeps Their Buy Rating on Sanofi (SNYNF)

Nicolas Pauillac

Kepler Capital

€85

Hold

11.62%

Upside

Reiterated

04/23/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF) and Sanofi (Other OTC: SNYNF)

James Gordon CFA

Barclays

€85

Hold

11.62%

Upside

Reiterated

04/23/26

Analysts Conflicted on These Healthcare Names: BridgeBio Oncology Therapeutics (NASDAQ: BBOT), Sanofi (Other OTC: SNYNF) and Molina Healthcare (NYSE: MOH)

Graham Parry

Citi

€85→€80

Hold

5.06%

Upside

Reiterated

02/20/26

Sanofi price target lowered to EUR 80 from EUR 85 at CitiSanofi price target lowered to EUR 80 from EUR 85 at Citi

David Risinger

Leerink Partners

―

Buy

―

Reiterated

12/24/25

Analysts' Top Healthcare Picks: Sanofi (SNYNF), Genmab (GMAB)

Rajesh Kumar

HSBC

€102→€100

Buy

31.32%

Upside

Reiterated

12/10/25

Sanofi price target lowered to EUR 100 from EUR 102 at HSBCSanofi price target lowered to EUR 100 from EUR 102 at HSBC

Seamus Fernandez

Guggenheim

€104→€101

Buy

32.63%

Upside

Reiterated

10/08/25

Sanofi price target lowered to EUR 101 from EUR 104 at GuggenheimSanofi price target lowered to EUR 101 from EUR 104 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sanofi

3 Months

David RisingerLeerink Partners

Success Rate

19/35 ratings generated profit

Average Return

-0.30%

Copying David Risinger's trades and holding each position for 3 Months would result in 54.29% of your transactions generating a profit, with an average return of -0.30% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

19/35 ratings generated profit

Average Return

+2.21%

Copying David Risinger's trades and holding each position for 1 Year would result in 54.29% of your transactions generating a profit, with an average return of +2.21% per trade.

2 Years

Emmanuel PapadakisDeutsche Bank

Success Rate

23/55 ratings generated profit

Average Return

-1.67%

Copying Emmanuel Papadakis's trades and holding each position for 2 Years would result in 41.82% of your transactions generating a profit, with an average return of -1.67% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SNW Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SNW has received 11 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. SNW average Analyst price target in the past 3 months is 94.40.

Each month's total comprises the sum of three months' worth of ratings.

SNW Financial Forecast

SNW Earnings Forecast

Next quarter’s earnings estimate for SNW is €2.89 with a range of €2.65 to €3.22. The previous quarter’s EPS was €2.09. SNW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year SNW has Performed in-line its overall industry.

SNW Sales Forecast

Next quarter’s sales forecast for SNW is €13.76B with a range of €13.00B to €14.39B. The previous quarter’s sales results were €22.11B. SNW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year SNW has Performed in-line its overall industry.

SNW Stock Forecast FAQ

What is DE:SNW’s average 12-month price target, according to analysts?

Based on analyst ratings, Sanofi’s 12-month average price target is 94.40.

What is DE:SNW’s upside potential, based on the analysts’ average price target?

Sanofi has 23.97% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sanofi a Buy, Sell or Hold?

Sanofi has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 4 hold ratings and 0 sell ratings.

What is Sanofi’s share price target?

The average share price target for Sanofi is 94.40. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €106.21 ,and the lowest forecast is €78.00. The average share price target represents 23.97% Increase from the current price of €76.15.

What do analysts say about Sanofi?

Sanofi’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Sanofi?

To buy shares of DE:SNW, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Sanofi (SNW) Stock Forecast & Price Target

SNW Analyst Ratings

SNW Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sanofi

SNW Analyst Recommendation Trends

SNW Financial Forecast

SNW Earnings Forecast

SNW Sales Forecast

SNW Stock Forecast FAQ

Detailed List of Analyst Forecasts